Brazil to produce its own infliximab
This article was originally published in Scrip
Executive Summary
Brazil is to manufacture its own version of Janssen's monoclonal antibody Remicade (infliximab), thanks to a technology transfer deal with Janssen worth R$206mn ($80mn), says the health ministry.